Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ACTRN12626000947303) titled 'Study to evaluate the safety, effects, and early effectiveness of IDB-1829 in combination with Enzalutamide in patients with advanced prostate cancer' on July 30.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Primary Sponsor: Interdict Bio
Condition:
Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Cancer - Prostate
Intervention:
- Participants will receive IDB-1829 orally once daily in combination with enzalutamide 160 mg orally once daily, administered in continuous 21-day treatment cycles. IDB-1829 will be ev...